Cytisinicline For E-Cigarette Cessation—Reply-Reference-Cited by-同舟云学术

Cytisinicline For E-Cigarette Cessation—Reply

Published:2024-09-09 Issue: Volume: Page:
ISSN:2168-6106
Container-title:JAMA Internal Medicine
language:en
Short-container-title:JAMA Intern Med

Author:

Rigotti Nancy A.¹,Benowitz Neal L.²,Jacobs Cindy³

Affiliation:

1. Tobacco Research and Treatment Center, Division of General Internal Medicine and Mongan Institute, Department of Medicine, Massachusetts General Hospital, Harvard Medical School, Boston

2. Research Program in Clinical Pharmacology, Division of Cardiology, Department of Medicine, University of California San Francisco, San Francisco

3. Achieve Life Sciences, Inc, Seattle, Washington

Publisher

American Medical Association (AMA)

Link

https://jamanetwork.com/journals/jamainternalmedicine/articlepdf/2823424/jamainternal_rigotti_2024_lr_240020_1725042506.25411.pdf

Reference5 articles.

1. Cytisinicline for vaping cessation in adults using nicotine e-cigarettes: the ORCA-V1 randomized clinical trial.;Rigotti;JAMA Intern Med,2024

2. Cytisinicline for smoking cessation: a randomized placebo-controlled phase 3 clinical trial.;Rigotti;JAMA,2023

3. A phase I, double-blind, randomized, placebo-controlled, single dose-escalation study to evaluate the tolerability, and safety of cytisinicline in adult smokers.;Jacobs;Nicotine Tob Res,2023

4. Achieve Life Sciences announces initiation of ORCA-OL clinical trial evaluating long-term exposure of cytisinicline in people who smoke or use nicotine e-cigarettes. Achieve Life Sciences. Published May 29, 2024. Accessed July 7, 2024. https://ir.achievelifesciences.com/news-events/press-releases/detail/199/achieve-life-sciences-announces-initiation-of-orca-ol

5. Study to evaluate electrocardiographic effects of therapeutic & supratherapeutic doses of cytisinicline in healthy smokers. ClinicalTrials.gov. Updated May 2023. https://clinicaltrials.gov/study/NCT05566288